Publication | Closed Access

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial

Healthcare-associated InfectionSkin Structure InfectionsAcute Bacterial SkinAntimicrobial ChemotherapyInfection ControlDermatologyMedicineClinical MicrobiologyAntimicrobial ResistanceOral Linezolid